Logo image of 6IV.DE

INVENTIVA SA (6IV.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:6IV - FR0013233012 - Common Stock

3.41 EUR
+3.41 (+Infinity%)
Last: 11/24/2025, 7:00:00 PM
Fundamental Rating

1

Taking everything into account, 6IV scores 1 out of 10 in our fundamental rating. 6IV was compared to 81 industry peers in the Biotechnology industry. 6IV has a bad profitability rating. Also its financial health evaluation is rather negative. 6IV is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

6IV had negative earnings in the past year.
In the past year 6IV has reported a negative cash flow from operations.
6IV had negative earnings in each of the past 5 years.
In the past 5 years 6IV always reported negative operating cash flow.
6IV.DE Yearly Net Income VS EBIT VS OCF VS FCF6IV.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -154.84%, 6IV is not doing good in the industry: 85.19% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -154.84%
ROE N/A
ROIC N/A
ROA(3y)-120.12%
ROA(5y)-85.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
6IV.DE Yearly ROA, ROE, ROIC6IV.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

6IV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
6IV.DE Yearly Profit, Operating, Gross Margins6IV.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

0

2. Health

2.1 Basic Checks

6IV does not have a ROIC to compare to the WACC, probably because it is not profitable.
6IV has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, 6IV has more shares outstanding
The debt/assets ratio for 6IV has been reduced compared to a year ago.
6IV.DE Yearly Shares Outstanding6IV.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
6IV.DE Yearly Total Debt VS Total Assets6IV.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

6IV has an Altman-Z score of -5.14. This is a bad value and indicates that 6IV is not financially healthy and even has some risk of bankruptcy.
6IV has a Altman-Z score of -5.14. This is in the lower half of the industry: 6IV underperforms 72.84% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.14
ROIC/WACCN/A
WACC7.78%
6IV.DE Yearly LT Debt VS Equity VS FCF6IV.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 0.92 indicates that 6IV may have some problems paying its short term obligations.
6IV has a worse Current ratio (0.92) than 74.07% of its industry peers.
6IV has a Quick Ratio of 0.92. This is a bad value and indicates that 6IV is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of 6IV (0.92) is worse than 71.60% of its industry peers.
Industry RankSector Rank
Current Ratio 0.92
Quick Ratio 0.92
6IV.DE Yearly Current Assets VS Current Liabilites6IV.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for 6IV have decreased strongly by -74.14% in the last year.
6IV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -12.84%.
Measured over the past years, 6IV shows a small growth in Revenue. The Revenue has been growing by 5.62% on average per year.
EPS 1Y (TTM)-74.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.33%
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y29.92%
Revenue growth 5Y5.62%
Sales Q2Q%10763.41%

3.2 Future

6IV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.26% yearly.
6IV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 123.56% yearly.
EPS Next Y38.93%
EPS Next 2Y23.83%
EPS Next 3Y13.14%
EPS Next 5Y16.26%
Revenue Next Year-14.87%
Revenue Next 2Y-46%
Revenue Next 3Y70.9%
Revenue Next 5Y123.56%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
6IV.DE Yearly Revenue VS Estimates6IV.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
6IV.DE Yearly EPS VS Estimates6IV.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

6IV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year 6IV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
6IV.DE Price Earnings VS Forward Price Earnings6IV.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
6IV.DE Per share data6IV.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

6IV's earnings are expected to grow with 13.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.83%
EPS Next 3Y13.14%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 6IV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INVENTIVA SA

FRA:6IV (11/24/2025, 7:00:00 PM)

3.41

+3.41 (+Infinity%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-21 2025-11-21
Earnings (Next)02-16 2026-02-16/amc
Inst Owners55.69%
Inst Owner ChangeN/A
Ins Owners6.82%
Ins Owner ChangeN/A
Market Cap651.37M
Revenue(TTM)13.61M
Net Income(TTM)-184.21M
Analysts86.15
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 70.82
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.62
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS0.05
BVpS-0.56
TBVpS-0.56
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -154.84%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.12%
ROA(5y)-85.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.41%
Cap/Sales 3.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.92
Quick Ratio 0.92
Altman-Z -5.14
F-Score3
WACC7.78%
ROIC/WACCN/A
Cap/Depr(3y)20.07%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.77%
Cap/Sales(5y)20.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-74.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.33%
EPS Next Y38.93%
EPS Next 2Y23.83%
EPS Next 3Y13.14%
EPS Next 5Y16.26%
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y29.92%
Revenue growth 5Y5.62%
Sales Q2Q%10763.41%
Revenue Next Year-14.87%
Revenue Next 2Y-46%
Revenue Next 3Y70.9%
Revenue Next 5Y123.56%
EBIT growth 1Y6.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.67%
EBIT Next 3Y15.84%
EBIT Next 5Y21.53%
FCF growth 1Y-5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.29%
OCF growth 3YN/A
OCF growth 5YN/A

INVENTIVA SA / 6IV.DE FAQ

What is the fundamental rating for 6IV stock?

ChartMill assigns a fundamental rating of 1 / 10 to 6IV.DE.


What is the valuation status for 6IV stock?

ChartMill assigns a valuation rating of 0 / 10 to INVENTIVA SA (6IV.DE). This can be considered as Overvalued.


What is the profitability of 6IV stock?

INVENTIVA SA (6IV.DE) has a profitability rating of 0 / 10.


What is the financial health of INVENTIVA SA (6IV.DE) stock?

The financial health rating of INVENTIVA SA (6IV.DE) is 0 / 10.


Can you provide the expected EPS growth for 6IV stock?

The Earnings per Share (EPS) of INVENTIVA SA (6IV.DE) is expected to grow by 38.93% in the next year.